We have cloned a receptor, named LSCPR, for vasopressin-related Lys-conopressin in Lymnaea stagnails. Lys-conopressin evokes Ca2+-dependent Cicurrents in Xenopus oocytes injected with LSCPR cRNA. Expression of LSCPR mRNA was detected in central neurons and peripheral muscles associated with reproduction. Upon application of Lys-conopressin, both neurons and muscle cells depolarize owing to an enhancement of voltage-dependent Ca 2+ currents and start firing action potentials. Some neurons coexpress LSCPR and Lys-conopressin, suggesting an autotransmitter-like function for this peptide. Lysconopressin also induces a depolarizing response in LSCPR-expressing neuroendocrine cells that control carbohydrate metabolism. Thus, in addition to oxytocin-like reproductive functions, LSCPR mediates vasopressin-like metabolic functions of Lys-conopressin as well.
Introduction
In mammals, the nonapeptides vasopressin and oxytocin have important functions in the control of osmoregulation and reproduction, respectively (reviewed in Cunningham and Sawchenko, 1991) . These functions are mediated by pharmacologically distinct receptors (Jard et al., 1987) . Recent cloning studies have shown that these receptors belong to a family of structurally related G protein-coupled receptors. The V2 vasopressin receptor mediates the antidiuretic effects of vasopressin and couples positively to adenylate cyclase (Birnbaumer et al., 1992; Lolait et al., 1992; Gorbulev et al., 1993) . The Vla ; §Present address: Universit&t Potsdam and Deutsches Institut for Ern&hrungsforschung, Arthur-Scheunert-Allee 114-116, D-14558 Potsdam-RehbrQcke, Germany. Thibonnier et al., 1994) and the Vl b (Sugimoto et al., 1994) vasopressin receptors, which mediate the effects of vasopressin on liver glycogenolysis and adenocorticotropin release, respectively, as well as the oxytocin receptor (Kimura et al., 1992; Gorbulev et al., 1993) , which mediates the various central and peripheral functions in reproduction of oxytocin, all couple to the inositol trisphosphate (IP3)/Ca 2+ signal transduction pathway. Vasopressin and oxytocin are structurally and functionally distinguished by the chemical nature of the amino acid residues at position 8. In vasopressin (and all peptides related to vasopressin), this residue is a basic residue, whereas in oxytocin (and all peptides related to oxytocin), it is a neutral, in most cases aliphatic, residue (see Acher, 1993 , for review). Distinct vasopressin and oxytocin lineages originate from the duplication of a single ancestral gene early during vertebrate evolution (Acher, 1980; . However, the concomitant evolution of distinct classes of receptors for the two types of peptide, in particular the codevelopment of specificity determinants in the receptors, is poorly understood. Peptides and receptors of the vasopressin/oxytocin superfamily offer an attractive model for studies of the molecular basis of the specificity of peptide-receptor interactions, because specific receptor binding is mainly determined by the chemical nature of a single amino acid residue in the peptides (Sharif and Hanley, 1992) . It would be very useful, however, to have at our disposal an ancestral form of receptor that can be used as an experimental tool in the determination of specificity domains.
In invertebrates, the vasopressin-related peptide Lysconopressin is widely distributed throughout the different phyla (Cruz et al., 1987; McMaster et al., 1992; Salzet et al., 1993; Nielsen et al., 1994; . Although oxytocin-related peptides have also been structurally identified in invertebrates (Reich, 1992; Oumi et al., 1994) , co-occu rrence of vasopressin-and oxytocin-related peptides has never been demonstrated in the same species. Moreover, the Lys-conopressin gene is the only member of the vasopressin/oxytocin gene superfamily present in the mollusc Lymnaea stagnalis , which supports the hypothesis that the primordial gene duplication that gave rise to distinct vasopressin and oxytocin lineages occurred during vertebrate evolution and suggests that species variation and not gene duplication explains the occurrence of both vasopressin-and oxytocin-related peptides in invertebrates. Lys-conopressin is synthesized by central neurons and functions as a neurotransmitter/neuromodulator in both the brain and the male copulatory organs . It induces contractions of the vas deferens, thus stimulating the ejaculation of semen during copulation, and inhibits central neuroendocrine cells that coordinate female reproductive behavior. Thus, although structurally related to vasopressin, Lys-conopressin controls reproductive functions that are clearly analogous to the central and myoregulatory functions of oxytocin in vertebrate reproduction.
As these findings suggest that both vasopressin and oxytocin may have evolved from a Lys-conopressin-like ancestral peptide, the Lys-conopressin receptor may also display characteristics of an ancestral receptor that preceded the vasopressin and the oxytocin receptor lineages in vertebrates. We have now structurally identified a receptor for Lys-conopressin. This receptor, named L. stagnalis conopressin receptor (LSCPR), is structurally related to both vasopressin and oxytocin receptors. Functional expression in Xenopus laevis oocytes reveals that LSCPR is most likely coupled to the IP3/Ca 2+ signal transduction pathway, a characteristic that is shared with both V1 type vasopressin and oxytocin receptors. Moreover, the tissue and neuronal distribution of LSCPR, together with electrophysiological measurements of muscle cells and central neurons that express LSCPR, indicates that it mediates oxytocin-like reproductive functions as well as vasopressin-like metabolic functions of Lys-conopressin.
Results
Cloning of LSCPR PCR on vas deferens cDNA using primers TM6s and TM7as yielded mixtures of amplified cDNAs. When products with the expected size of 150 bp were cloned into pBluescript and sequenced, four different cDNAs were found, all encoding putative G protein-coupled receptor fragments. Database searches revealed that one of the cloned cDNAs encoded a protein fragment having a significantly higher sequence identity with vasopressin and oxytocin receptors than with any other G protein-coupled receptor. This fragment was used to screen brain-specific XZAPII cDNA libraries for full-length clones. Of 4 x 108 independent clones that were screened, 1 hybridized and was isolated. The corresponding pBluescript phagemid, named pBSCPR, was rescued by in vivo excision and sequenced, pBSCPR has an insert of 5.0 kb and contains an open reading frame of 1386 bp encoding a 462 amino acid protein with a predicted molecular mass of 52.2 kDa ( Figure 1A ). The open reading frame is preceded by an in-frame stop codon at position -57, which indicates that the coding region is complete at the 5' end. Although inframe ATG sequences are also present at nucleotides 34 and 40, the ATG at position I is suggested to be the translation initiation site since it best fits the GCC(A/G)CCATGG Kozak consensus sequence for initiation of translation (Kozak, 1987) .
Structural Characteristics of LSCPR
Hydrophobicity analysis (Kyte and Doolittle, 1982) of the predicted amino acid sequence revealed seven hydrophobic domains characteristic for the seven transmembrane domains (TMs) of G protein-coupled receptors (Figure 1 B ; Baldwin, 1993) . Therefore, and because of its sequence identity with vasopressin and oxytocin receptors, the predicted protein was tentatively named L. stagnalis conopressin receptor (LSCPR). LSCPR contains several potential sites for N-linked glycosylation and for phosphorylation ( Figure 1A ). Consensus sequences for N-linked glycosylation (Asn-X-Ser/Thr) occur predominantly in the extracellular N-terminal domain and may have a function in targeting the receptor protein to the plasma membrane (Ostrowski et al., 1992) since the protein lacks a hydrophobic signal sequence. Consensus sequences for phosphorylation include eight sites for protein kinase C (Ser/Thr-X-Arg/Lys) and four for casein kinase II (Ser/Thr-X-X-Asp/Glu) and occur predominantly in the third intracellular loop (between TM5 and TM6) and in the C-terminus, suggesting that phosphorylation may be important in the modulation of G protein coupling and receptor function (Probst et al., 1992 ).
An amino acid sequence alignment of LSCPR and receptors for vasopressin, oxytocin, and vasotocin from vertebrates is presented in Figure 2 . In the region from the beginning of TM1 to the end of TM7, LSCPR has 43% sequence identity with the oxytocin receptor, the Vla and Vlb vasopressin receptors, and the vasotocin receptor and 39% sequence identity with the V2 vasopressin receptor. The N-terminal extracellular and the C-terminal intracellular domains of LSCPR are slightly longer than those of most vertebrate receptors. Also, the third intracellular loop is considerably longer, containing 26-40 amino acid residues more than the same loop in the various vertebrate receptors. Sequence identity is highest in the transmembrahe domains, especially in TM7, whereas the N-and C-terminal domains as well as the third intracellular loop show hardly any sequence identity.
In the first and second extracellular loops (between TM2 and TM3 and between TM4 and TM5, respectively), several amino acid residues are found (Figure 2 , asterisks) that are conserved among the members of the vasopressin/oxytocin receptor family in vertebrates but not in other G protein-coupled receptors. Since the two loops may be linked together by a disulphide bridge (Dohlman et al., 1990) and form a putative ligand binding pocket, these residues are thought to be important in ligand binding (Sharif and Hanley, 1992) . In LSCPR, these stretches of amino acid residues are conserved. The differences that are observed in the sequence PheGInValLeuProGInLeu at the end of TM2 involve conserved substitutions only (i.e., GInVal is replaced by Asnlle in LSCPR). However, in the sequences GlyProAsp and ProTrpGly (just before TM3 and TM5, respectively), the proline residues are both replaced by aspartate residues, introducing 2 additional negatively charged residues in the putative ligand binding pocket. In the sequence AspCysTrpAla (between TM4 and TM5), the tryptophane residue is replaced by a leucine residue.
Another conserved sequence is located in the third intracellular loop just before TM6. This part of the receptor is known to be involved in G protean coupling (Ostrowski et al., 1992) . Interestingly, the corresponding part in LSCPR has higher sequence identity with the oxytocin, V1 vasopressin, and vasotocin receptors, which are all coupled to the IPJCa 2+ signal transduction pathway, than with the V2 vasopressin receptor, which is coupled to adenylate cyclase. This may be indicative of the signal transduction characteristics of LSCPR. Two adjacent cysteines that are found 15 residues downstream of TM7 in all the vertebrate vasopressin and oxytocin receptors identified so far may be responsible for anchoring the C-terminus to the plasma membrane through palmitoylation, as has been observed for the ~-adrenergic receptor (O'Dowd et al., 1989). Since these cysteines are not present in LSCPR, its C-terminus is probably not linked to the plasma membrane through a palmitoylation anchor.
Functional Expression of LSCPR in Xenopus Oocytes
To demonstrate that LSCPR is a receptor for Lys-conopressin, we expressed the LSCPR cDNA in Xenopus oo- The initial fast inward current was typically followed by an oscillatory current, which is probably driven by intracellutar Ca 2+ oscillations and lasted for about 5 min after washing out of the peptide.
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(B) Dose-response curve of the effect of Lys-conopressin on the total membrane current. The total membrane currents elicited by 1.5 min applications of Lys-conopressin at different concentrations were integrated over time and plotted semilogarithmically versus the peptide concentration. The mean of three independent experiments is shown with SEM (error bars), and the ECs0 was calculated as 22 _+ 2 nM (mean -4-SD).
(C) Pharmacological characterization of LSCPR. Various vasopressinand oxytocin-retated peptides are listed in order of potency in eliciting membrane current responses in Xenopus oocytes expressing LSCPR. For the conopressins, estimated EC~0 values are indicated; for the less potent peptides, the threshold concentrations for receptor activation are indicated. Arg-vasopressin and isotocin are inactive.
possibility of detecting contaminant mRNA or cDNA, the experiment was performed in triplicate. Since we established the presence of an intron within the amplified sequence (data not shown), amplification of genomic DNA would have been noted, but did not occur. LSCPR mRNA is present in the vas deferens and the brain, but not in the other tissues mentioned ( Figure 4A ). Interestingly, the amount of cDNA amplified from the anterior part of the vas deferens is higher than the amount from the posterior part of the vas deferens, suggesting a difference in the amount of LSCPR mRNA present in the two parts of the vas deferens.
The localization of LSCPR mRNA in the brain was further investigated by in situ hybridization. One series of alternately collected sections of the brain was hybridized with a full-length LSCPR-specific antisense cRNA probe. LSCPR gene expression was detected in a number, but not all, of the neurons in the anterior lobes of the cerebral ganglia ( Figures 4C and 4E ). Since the anterior lobe neurons also express the Lys-conopressin gene , alternate sections were hybridized with a Lysconopressin-specific antisense cRNA probe in order to establish possible coexpression of LSCPR and Lysconopressin. Indeed, most of the neurons that express LSCPR express also Lys-conopressin; however, a few cells express exclusively LSCPR or Lys-conopressin (Figures 4B and 4D) . LSCPR gene expression could also be detected in a few neurons in the pedal Ib cluster in the right pedal ganglion ( Figure 4F ) and in some of the cerebral light green cells ( Figure 4G ). In addition, several unidentified neurons throughout the brain were found to express the LSCPR gene (data not shown). Control hybridizations with sense cRNA probes were all negative.
In the vas deferens, we failed to localize LSCPR gene expression by in situ hybridization. This might be due to a low expression level of the LSCPR mRNA in all muscle cells; in the brain, expression levels in individual cells might be higher, but expression is restricted to a small number of neurons. Furthermore, diffusion of the mRNA throughout the cytoplasm of the muscle cells, which are much larger than neurons, may have caused the hybridization signal to drop below the detection level.
Effects of Conopressin on Isolated Vas Deferens Muscle Cells, Anterior Lobe Cells, and Light Green Cells
To establish the presence of LSCPR on muscle cells of the vas deferens and to study the functional role of these receptors, we measured the electrophysiological effects of Lys-conopressin on muscle cells in vitro. In these experiments, dissociated muscle cells of the anterior and posterior vas deferens were studied separately, since these parts seem to express the LSCPR gene at different levels. Under current clamp, muscle cells from the anterior part responded to a 5 s application of Lys-conopressin at 10 -5 M (n = 4) with a slow, depolarizing potential lasting at least as long as the application. This depolarization gave rise to one or more all or none muscle spikes with a fast upstroke and decay, about 50 mV in amplitude and lasting 2-3 s at half amplitude ( Figure 5A ). In two cells, the slow depolarization strongly outlasted the application and evoked several muscle spikes or plateau potentials of up to 10 s duration ( Figure 5B ). In cells from the posterior vas deferens, we observed only a small depolarization, which failed to induce muscle spikes ( Figure 5C ).
The responses were investigated further under wholecell voltage clamp. Under control conditions, cells of the anterior vas deferens revealed a time-and voltage-dependent response upon step depolarizations. This response consisted of a small, initial inward current followed by a much larger outward current ( Figure 6A ). The outward current was biphasic, suggesting that it consisted of at least two different K + currents. Inward currents were observed from -60 to -10 mV, and outward currents appeared at voltages of t>-20 inV. Lys-conopressin (applied at 10 -s M; n = 4) induced multiple changes in these volt- age-dependent currents ( Figures 6B and 6C) . First, it increased the inward current and extended its voltage range to +30 mV ( Figure 6B ). Difference plots obtained by subtraction of control traces from responses in the presence of Lys-conopressin revealed that Lys-conopressin induced a new inward current component with fast apparent kinetics of activation and inactivation. In addition, Lysconopressin increased the initial, fast outward current ( Figure 6C ). The effects of Lys-conopressin on the slow outward current varied between cells. Both an increase and a decrease in the amplitude of this current were observed (data not shown), whereas in some cells, its amplitude was not affected ( Figure 6C ). This variability suggests that the net effects on the slow outward current are due to changes in more than one current, possibly a Ca ~+ current and a Ca2+-dependent K + current. To investigate the possible contribution of a Ca 2+ current to the Lys-conopressin-induced changes in the total membrane current, we studied the effects of Lys-conopressin on the isolated Ca 2+ current. Under control conditions, this current consisted of a low voltage-activated, transient component (activation at >t-40 mV) with fast kinetics of inactivation and a high voltage-activated component (activation at >/-10 mY) that inactivated more slowly ( Figure 7A ). Lysconopressin (applied at 10 5 M; n = 2) strongly increased the amplitude of the high voltage-activated component without affecting its kinetics or voltage dependence (Figures 7B and 7C) . Cells of the posterior vas deferens under voltage clamp were not affected by Lys-conopressin. Neither the inward nor the outward current changed in amplitude when Lysconopressin was applied (n = 4). Together, these findings strongly suggest that only muscle cells of the anterior vas deferens, and not those of the posterior vas deferens, express LSCPR, which may explain the difference in the amounts of LSCPR cDNA that could be amplified from the two parts of the vas deferens.
In addition to vas deferens muscle cells, we studied the effect of Lys-conopressin on central neurons that express the LSCPR gene. Light green cells and neurons in the right anterior lobe were recorded under current clamp. In light green cells in primary cell culture, Lys-conopressin (applied at 10 e M for 5 s; n = 3) induced a depolarizing response that triggered a burst of action potential activity that lasted for -3 0 s (see Figure 5D ). Neurons in the right anterior lobe were recorded in situ, in the isolated nervous system. Some of these cells responded to 20 s applications of Lys-conopressin (at 10 -~ M) with a depolarization followed by a burst of action potential activity that lasted for -5 min (see Figure 5E ). Three anterior lobe neurons were positive in all five preparations tested. All responses were completely reversed when application was stopped and could be repeated several times.
Discussion

LSCPR Shares Structural and Signal Transduction Characteristics with both Vasopressin and Oxytocin Receptors
In a previous study , we demonstrated that, although Lys-conopressin is structurally related to vasopressin, it has functional characteristics that are usually associated with oxytocin. The aim of the present study is to clone the Lys-conopressin receptor and to characterize it structurally as well as functionally in order to gain insight into the evolution of functionally distinct vasopressin and oxytocin lineages. We used degenerate oligonucleotides directed to conserved sequences in recently cloned vasopressin and oxytocin receptors (Birnbaumer et al, 1992; Kimura et al., 1992; Lolait et al., 1992; Morel et al., 1992; Gorbulev et al., 1993; Sugimoto et al., 1994; Thibonnier et al., 1994) to amplify similar sequences from Lymnaea vas deferens cDNA. One of the amplification products did have the expected size and exhibited a high degree of sequence identity with both vasopressin and oxytocin receptor sequences. This fragment was used to isolate a full-length cDNA clone. Hydrophobicity analysis of the predicted LSCPR protein revealed seven hydr•phobic regions similar to the seven transmembrane domains found in all members of the G protein-coupled receptor superfamily. Several lines of evidence indicate that LSCPR is a functional Lys-conopressin receptor and a member of the vasopressin/oxytocin receptor family. First, the overall sequence identity of LSCPR is higher with the vasopressin and oxytocin receptors than with any other G protein-coupled receptor. Second, conserved sequences in the first and second extracellular loops of the vasopressin and oxytocin receptors that have been suggested to be involved in ligand binding (Sharif and Hanley, 1992) are present in LSCPR. Third, the tissue distribution of LSCPR is in good agreement with earlier observed functions of Lys-conopressin in the control of male sexual be-havior . Fourth, at physiological concentrations only Lys-conopressin activates LSCPR when functionally expressed in Xenopus oocytes, whereas other vasopressin-and oxytocin-related peptides do so only at higher concentrations or not at all. The LSCPR protein has the highest sequence identity with the Vla and Vlb vasopressin receptors and with the oxytocin receptor from mammals, as well as with the vasotocin receptor from teleost fish (see Figure 2) , which all couple to the IP3/Ca 2+ signaling pathway. Sequence identity is lower with the V2 vasopressin receptor, which couples to adenylate cyclase and specifically mediates the antidiuretic effects of vasopressin in mammals. Assuming that these observations are indicative for the signal transduction characteristics of LSCPR, we expressed LSCPR in Xenopus oocytes, which respond to an increase in intracellular Ca 2÷ concentrations by displaying an inward membrane CI-current. This response is characteristic for receptors that activate the IP3/Ca 2+ signal transduction pathway (Meyerhof et al., 1988) . Oocytes injected with LSCPR cRNA respond to application of Lys-conopressin with a fast increase in intracellular Ca 2+ levels, followed by Ca 2+ oscillations that last for about 5 min after washing out of the ligand. Vasopressin elicits a similar intracellular Ca 2+ response in oocytes expressing the V1 a vasopressin receptor (Nathanson et al., 1992) . This response involves the mobilization of Ca 2+ from IP3-sensitive intracellular stores. Based on our observations and in analogy with the Vla vasopressin receptor, we conclude that LSCPR most likely couples to the IP3/Ca 2+ signal transduction pathway.
LSCPR Is Selectively Activated by Lys-Conopressin
We pharmacologically characterized LSCPR by studying the potencies of vasopressin-and oxytocin-related peptides in eliciting membrane current responses in Xenopus oocytes expressing the LSCPR protein (see Figure 3C ). The three most potent peptides are the conopressins, indicating that the arginine residue at position 4 of these peptides, which is the only structural characteristic that distinguishes the conopressins from their vertebrate counterparts, is probably important in peptide-receptor interaction. Interestingly, the putative ligand binding pocket in LSCPR contains 2 negatively charged aspartate residues that are not found in the vertebrate receptors (see Figure  2) . Either of these may be important in binding the positively charged arginine residue in the conopressins. From the order of potency of the other vasopressin-and oxytocin-related peptides, several constraints on amino acid residues 2-4 can be inferred. At position 2, the presence of an aromatic amino acid residue seems to be important, since Arg-conopressin, which contains an isoleucine residue at this position, is 10 times less potent than Lysconopressin. At position 3, a nonaromatic hydrophobic residue is preferred, since Arg-vasopressin, which has a phenylalanine residue at this position, is inactive. At position 4, glutamine, but not serine, can replace the arginine residue to some extent, indicating the importance of a free amide group at this position. Thus, conformational flexibility in the N-terminal ring (residues 1-6) seems to be limited, and therefore this part of the molecule is probably involved in high affinity binding to the receptor.
In vasopressin and oxytocin, the C-terminal part of the peptide, in particular residue 8, is thought to be responsible for the discriminative binding of the peptides to their respective receptors (Acher, 1993) . We have previously predicted the presence of a Lys-conopressin receptor that is nondiscriminative with respect to residue 8 (Van , since Lys-conopressin and Ile-conopressin, an oxytocin-like analog of Lys-conopressin with the lysine residue at position 8 substituted with isoleucine, have similar bioactive potencies. Interestingly, LSCPR displays discriminative binding of Lys-conopressin and lleconopressin (see Figure 3C) , suggesting that an additional, nondiscriminative receptor subtype may exist in Lymnaea.
LSCPR Mediates both Vasopressin-and Oxytocin-like Functions of Lys-Conopressin
The LSCPR mRNA is predominantly present in tissues and central neurons that are involved in male copulatory behavior (i.e., the vas deferens [see Figure 4A ], neurons of the anterior lobe of the right cerebral ganglion [see Figures 4C and 4E] , and neurons of the pedal Ib cluster [see Figure 4F ]), suggesting a major role for LSCPR in the control of male reproductive behavior. To understand the functional role of LSCPR in the control of vas deferens activities, we tested the electrophysiological effects of Lysconopressin on smooth muscle cells from either the anterior or posterior part of the vas deferens in primary cell culture& Interestingly, muscle cells from the anterior part responded much more strongly to Lys-conopressin than muscle cells of the posterior part (see Figures 5A and 5B) . Cells of the anterior part strongly depolarized and fired several action potentials in response to single applications of Lys-conopressin. Whole-cell voltage-clamp experiments revealed that this response is the result of changes in several voltage-dependent currents (see Figure 6 ). Most prominently, Lys-conopressin strongly enhanced the voltage-dependent Ca 2+ current (see Figure 7) . The increase in outward current observed in some preparations probably results from the stimulation of a Ca2+-dependent K + current caused by the increased inward Ca 2÷ current. Whether the appearance of a fast, transient inward current in the total current measurements (see Figure 6 ) is completely caused by the increase in Ca 2+ current is unclear. Possibly, an increase in a different inward current, e.g., a Na + current, contributes to this response as well. Also, further experiments are needed to demonstrate that the Lys-conopressin-induced changes in voltage-dependent currents are all caused by the presumed activation of the IP3/Ca 2÷ signal transduction pathway and the concomitant activation of protein kinase C. In contrast to the muscle cells of the anterior vas deferens, cells of the posterior vas deferens were only slightly depolarized by Lysconopressin. Under voltage clamp, no Lys-conopressininduced changes were observed, in neither voltagedependent nor -independent currents.
These findings strongly suggest that LSCPR is exclu-sively expressed on the cell surface of smooth muscle cells from the anterior part of the vas deferens. Since in vitro preparations of both parts of the vas deferens are equally responsive to Lys-conopressin , we hypothesize that in the posterior part Lysconopressin most likely modulates the release of other excitatory transmitters through an interaction with presynaptically expressed Lys-conopressin receptors. The small amount of LSCPR cDNA amplified from the posterior part may be derived from mRNA that has diffused into the axonal compartment of the neurons that express these presynaptic receptors. These neurons are probably the neurons of the anterior lobe and the pedal Ib cluster mentioned above, since they project into the penis nerve and innervate the male copulatory organs (Smit et al., 1992) , including the vas deferens . Lys-conopressin also has a strong excitatory effect on neurons in the right anterior lobe (see Figure 5E ). Some, but not all, of the cells responded to application of Lysconopressin with a short burst of action potentials, which is in good agreement with the fact that not all cells in the lobe express the LSCPR gene (see Figures 4C and 4E ). Because the majority of the anterior lobe cells that express LSCPR also express Lys-conopressin (see Figures 4B and  4D) , we suggest that Lys-conopressin acts as an excitatory autotransmitter on these cells and may play a role in the generation of electrical discharge activity in these cells. Similarly, autotransmitter-like functions have been reported for both oxytocin (Moos and Richard, 1989) and vasopressin (Wotjak et al., 1994) on magnocellular neurons in the rat.
In addition to the different types of neurons involved in the control of reproductive behavior, some of the neuroendocrine light green cells express the LSCPR gene. These cells synthesize and release insulin-related peptides (Smit et al., 1988; Li et al., 1992) , which control somatic growth and glycogen metabolism in Lymnaea (Geraerts, 1992) . Lys-conopressin induces a depolarizing response that triggers action potential firing in isolated light green cells (see Figure 5D ), indicating that it may stimulate the release of insulin-related peptides. Preliminary experiments indicate that, as in anterior vas deferens muscle cells, enhancement of the voltage-dependent Ca 2÷ current is involved in this response. Interestingly, vasopressin stimulates the release of insulin from pancreatic ~ cells in the rat (Hughes et al., 1992) , suggesting a conserved role for vasopressin (-related) peptides in the modulation of insulin (-related peptide) release in both mammals and molluscs.
In conclusion, we have cloned a novel member of the vasopressin/oxytocin receptor family that shares structural and signal transduction characteristics with both vasopressin and oxytocin receptors and mediates vasopressin-as well as oxytocin-like functions of Lys-conopressin. These findings indicate that LSCPR may represent an ancestral receptor to both vasopressin and oxytocin receptors. However, LSCPR does not display nondiscriminative binding properties with respect to the amino acid residue at position 8 in the ligand, which functionally distinguishes vasopressin from oxytocin. Studies of Lys-conopressin receptor diversity and the possible existence of nondiscriminative receptors may further contribute to our understanding of the historic development of determinants that specify peptide-receptor interactions in the vasopressin/ oxytocin superfamily of peptides and their cognate receptors.
Experimental Procedures
Animals and Peptides
Adult specimens of L. stagnalis (shell height 28-34 mm), bred in the laboratory under standard conditions, were used. Arg-vasopressin, Arg-vasotocin, Lys-vasotocin, oxytocin, mesotocin, and isotocin were obtained from Saxon Biochemicals (Hannover, Germany). Lys-conopressin and Arg-conop ressin were obtained from Bachem Feinchemikalien AG (Budendorf, Switzerland). ile-conopressin was synthesized as described .
Cloning and Sequencing of LSCPR
Poly(A) ÷ RNA was isolated from dissected vas deferens of L. stagnalis and reverse transcribed into oligo(dT17)-primed cDNA using 200 U of M-MLV reverse transcriptase (GIBCO-BRL). Two degenerate oligonucleotides, TM6s (5'-GGGAATTCG(GT)N(AG)(CT)NTT(CT)N(CT)N (ACT)TNTG(CT)TGGN(CT)NCC-3'), directed to a conserved region in TM6 of neuropeptide receptors in general, and TM7as (5'-CCGGAT-CC(AG)TA(AGT)ATCCANGG(AG)TT(AG)CA(AG)C-3'), directed to a conserved region in TM7 of vasopressin and oxytocin receptors, were used to amplify vasopressin and oxytocin receptor-like sequences. The primers contained at the 5' end a recognition sequence for the restriction endonucleases EcoRI and BamHI, respectively. PCR was performed in a 100 ~1 solution containing ten animal equivalents of vas deferens cDNA, each of the four deoxynucleotides (at 200 I~M), 150 pmol of each of the primers TM6s and TM7as, 10 mM Tris-HCI (pH 8.4), 0.1 mg/ml gelatin, 50 mM KCI, 1.5 mM MgCI2, and 2.5 U of Taq DNA polymerase (Perkin-Elmer Cetus). The PCR mixture was overlaid with 70 I~1 of mineral oil and incubated in a DNA thermal cycler (Perkin-Elmer Cetus) for 50 cycles of 1 rain at 94°C, 1 min at 50°C, and 1 min at 72°C. Amplified cDNA fragments were digested with EcoRI and BamHI and separated on agarose gel. Fragments of the expected size were isolated, cloned into pBluescript (Stratagene), and sequenced. One fragment was used to screen several Lymnaea brainspecific XZAPII cDNA libraries to obtain a full-length clone. The insertcontaining pBluescript phagemid corresponding to this clone (pBSCPR) was rescued by in vivo excision and sequenced.
Functional Expression of LSCPR in Xenopus Oocytes
The protein-encoding region of pBSCPR was amplified using primers directed to the translation initiation and termination sequences of the cDNA. At the 5' end, the primers contained a recognition sequence for the restriction endonucleases BamHI and EcoRI, respectively. The sense primer contained the Kozak consensus sequence for transcrip~ tion initiation (CCACCATG; Kozak, 1987) to replace the Lymnaea sequence at this position. Amplification was carried out in a DNA thermal cycler using 3 U of Ultma DNA polymerase (Perkin-Elmer Cetus) under conditions recommended by the supplier. Reactions were incubated for 12 cycles of 15 rain at 94°C, 15 rain at 60°C, and 1.5 rain at 72°C. The cDNA fragment was digested with BamHI and EcoRI and ligated into pGEMHE (Liman et al., 1992) , and 5' capped cRNA was transcribed in vitro from a 3' end linearized plasmid using 40 U of T7 RNA polymerase and Cap-Scribe transcription buffer (Boehringer Mannhelm). After phenol extraction and ethanol precipitation, the cRNA was dissolved in bidistilled water, and 50 nl (-3 ng of RNA) was injected into Xenopus oocytes. After incubating the injected oocytes for 2-3 days at 20°C (for details, see Meyerhof et al., 1988) , two electrode voltage-clamped oocytes were challenged with 1.5 min applications of Lys-conopressin and various related peptides. Peptide-induced membrane currents were recorded at holding potentials of -50 mV. For Lys-conopressin, a dose-response curve was constructed by integrating the membrane currents over time and plotting these values (expressed as a percentage of the maximal membrane current) semi-logarithmically versus the ligand concentration. The ECs0 value was calculated from the mean of three experiments.
Localization of LSCPR Gene Expression
Male and female sex organs, kidney, skin, brain, salivary gland, and hepatopancreas were dissected, and total RNA was isolated from each tissue in triplicate. Equal amounts of RNA (3-5 ~g for each tissue) were reverse transcribed into oligo(dT17)-primed cDNA using 200 U of M-MLV reverse transcriptase (GIBCO-BRL), and 5% of each reaction was used directly in a PCR experiment. A sense primer located in TM6 (5'-TTGTCCAGATGTGGAGCGCC-3') and an antisense primer located just downstream of the stop codon (5'-AGATTCCAAGGGTTC-TCAAATGTGACG-3') were used to amplify LSCPR cDNA, and primers specific for Lymnaea fructose 1,6-biphosphate aldolase (R. E. V. K., unpublished data) were used as a positive control for each cDNA preparation. After 30 cycles of amplification, PCR products were separated on agarose gel, transferred to Hybond N + membrane (Amersham), hybridized to 5' end ~2P-labeled primers specific for each product, and autoradiographed.
For in situ hybridization, full-length digoxigenin-labeled runoff antisense RNA was synthesized from 5' end linearized ptasmid pBSCPR and from a plasmid containing the Lys-conopressin cDNA (Van Kesteren et al., 1992) , using 20 U of T3 RNA polymerase and digoxigenin-UTP labeling mixture (both from Boehringer Mannheim); labeled cRNAs were alcohol precipitated. Lymnaea brains were freeze-dried at -40°C, fixed with paraformaldehyde vapor (80°C for 1 hr), and embedded in paraffin. Sections of 7 p,m were alternately collected on poly-L-lysine-coated slides. Before hybridization, slides were pretreated with 0.2% pepsin in 0.2 N HCI at 37°C for 20 min and washed in bidistilled water. In situ hybridization was carried out as described (Tensen et al., 1991) , with the exception that the hybridization buffer contained 60% formamide and 2-5 ng/ml cRNA probe. One series of sections was incubated with the LSCPR probe, the other with the Lys-conopressin probe. Control slides were incubated with sense RNA probes. After 16 hr of hybridization at 48°C, slides were washed twice in 2x SSC at 20°C, once in 2x SSC containing 0.1 mg/ml RNase A at 37°C for 45 min, twice in t x SSC and in 0.5x SSC at 20°C, and twice in 0.2 x SSC and in 0.1 x SSC at 60°C. Hybrids were visualized using an alkaline phosphatase-conjugated anti-digoxigenin antiserum (Beehringer Mannheim).
Electrophysiological Recordings
Antibiotic saline was composed of 51.3 mM NaCI, 1.7 mM KCI, 4.1 mM CaCI2, 1.5 mM MgCI~, 5 mM HEPES (pH 7.9), and 150 p,g/ml gentamicin (Sigma). Defined medium consisted of serum-free 50% Liebowitz L-15 medium (GIBCO BRL) containing 40.0 mM NaCI, 1.7 mM KCI, 4.1 mM CaCI2, 1.5 mM MgCI2, 10.0 mM HEPES (pH 8.1), 150 p.g/ml L-glutarnine, 54 p.g/ml D-glucose, and 25 p.g/ml gentamicin (for details, see Ridgway et al., 1991) . Dissected anterior and posterior vas deferens was cut into pieces, washed 4 times for 10 rain in antibiotic saline, and incubated at 37°C for 2 hr in defined medium containing 0.3% coll~genase/dispase (Sigma). Cells were centrifuged at 600 x g for 10 r~in and washed 3 times in antibiotic saline. After removal of large debris, cells were resuspended in defined medium, transferred to poly-L-lysine-coated Falcon 3001 culture dishes, and stored at 4°C for 20 hr. Light green cells were isolated and cultured as described (Kits et al., 1991) . Cells in the anterior lobe of the right cerebral ganglion were recorded in situ in the isolated nervous system. Isolated cells and nervous systems were bathed in HEPES-buffered saline composed of 30 mM NaCI, 10 mM NaCH3SO4, 4 mM CaCI2, 1.5 mM MgCI2, 1.7 mM KCI, 5 mM NaHCO3, 10 mM HEPES (pH 7.8, adjusted with NaOH). Standard pipette saline used in whole-cell voltage-clamp recordings was composed of 29 mM KCI, 2.3 mM CaCI2, 2 mM Mg-ATP, 0,1 mM Tris-GTP, 11 mM EGTA, 10 mM HEPES (pH 7.4, adjusted with KOH). Ca 2+ currents were recorded after HEPESbuffered satine was replaced by 40 mM tetraethylammonium (TEA) chloride, 4 mM CaCI2, 2 mM MgCt2, 2 mM 4-aminopyridine, 10 mM HEPES (pH 7.8, adjusted with TEA-OH) under continuous perfusion. The pipette solution used in the Ca 2+ current recordings was composed of 29 mM CsCI, 2,3 mM CaCI2, 2 mM Mg-ATP, 0.1 mM Tris-GTP, 11 mM EGTA, 10 mM HEPES (pH 7.4, adjusted with CsOH). Lysconopressin was applied by means of a pressure ejection system through a small glass pipette ( -20 t~m tip diameter) placed -100 t~m from the recorded cell. Effects on current-voltage relations of voltagedependent currents were studied under continuous application of Lysconopressin during a series of depolarizing voltage steps.
Membrane potential recordings were made using sharp microelectrodes (-40 M~) filled with 0.5 M KCI and an Axoclamp 2A ampifier (Axon Instruments) in the bridge balance mode or a custom-built microelectrode amplifier. Whole-cell voltage-clamp recordings were made using the Axoclamp 2A amplifier in the continuous single-electrode voltage-clamp mode. Pipettes (2-6 M~) were pulled on a Flaming/ Brown P-87 horizontal microelectrode puller (Sutter Instruments) from Clark GC-150T glass (Clark Electromedical; seal resistance >1 G~). After disrupture of the patch membrane, series resistance (typically <5 M~) was compensated for -70% using the bridge balance control of the amplifier. Cell capacitance (-100 pF) was not compensated. To allow equilibration of the interior of the cell with the pipette solution, Ca 2+ current measurements were only started about 20 min after getting access to the cell.
Data acquisition was controlled using a CED 1401 AD/DA converter (Cambridge Electronics Design) connected to an Intel 80486-based computer run with voltage-clamp software developed in our laboratory. The current recordings were filtered at 1-5 kHz, sampled at 1 kHz, and stored on-line. This system allowed simultaneous application of voltage steps, acquisition of current recordings, and timed application of Lys-conopressin.
